CanSino Biologics
Total Raised
$95MInvestors Count
8Deal Terms
3Investments
1Funding, Valuation & Revenue
4 Fundings
CanSino Biologics has raised $95M over 4 rounds.
CanSino Biologics's latest funding round was a IPO for $161M on March 28, 2019.
CanSino Biologics's valuation in April 2017 was $384.82M.
CanSino Biologics's latest post-money valuation is from March 2019.
Sign up for a free demo to see CanSino Biologics's valuations in March 2019, November 2015 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
3/28/2019 | IPO | $161M | 3 | |||
4/1/2017 | Series C | ▲$384.82M | ||||
11/3/2015 | Series B | |||||
Other Investors |
Date | 3/28/2019 | 4/1/2017 | 11/3/2015 | |
|---|---|---|---|---|
Round | IPO | Series C | Series B | Other Investors |
Amount | $161M | |||
Investors | ||||
Valuation | ▲$384.82M | |||
Revenue | ||||
Sources | 3 |
CanSino Biologics Deal Terms
3 Deal Terms
CanSino Biologics's deal structure is available for 3 funding rounds, including their IPO from March 28, 2019.
Round | IPO | Series C | Series B |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO | |||||||||||||||
Series C | |||||||||||||||
Series B |
CanSino Biologics Investors
8 Investors
CanSino Biologics has 8 investors. Qiming Venture Partners invested in CanSino Biologics's Series C funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
11/3/2015 | 4/1/2017 | 2 Series B, Series C (2017) | Venture Capital | China | ||
Venture Capital | China | |||||
Venture Capital | China | |||||
Private Equity | China | |||||
Private Equity | China |
First funding | 11/3/2015 | ||||
|---|---|---|---|---|---|
Last Funding | 4/1/2017 | ||||
Investor | |||||
Rounds | 2 Series B, Series C (2017) | ||||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Venture Capital | Private Equity | Private Equity |
Location | China | China | China | China | China |
CanSino Biologics Investments
1 Investments
CanSino Biologics has made 1 investments. Their latest investment was in SOLBIO as part of their Corporate Minority on September 18, 2023.
CanSino Biologics Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/18/2023 | Corporate Minority | SOLBIO | Yes | 1 |
Date | 9/18/2023 |
|---|---|
Round | Corporate Minority |
Company | SOLBIO |
Amount | |
New? | Yes |
Co-Investors | |
Sources | 1 |
Compare CanSino Biologics to Competitors
Zydus Cadila is a fully integrated, global healthcare provider that strengthens parts all along the pharmaceutical value chain. Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products.
Takara Bio USA, Inc. is a company that provides life science research reagents and tools across various biological domains. The company offers products such as kits, reagents, instruments, and services for research in gene discovery, regulation, function, and stem cell research. Takara Bio serves sectors involved in molecular diagnostics, mRNA and protein therapeutics, pathogen detection, immunotherapy, cancer research, Alzheimer's disease research, reproductive health technologies, and infectious diseases. It was founded in 1984 and is based in San Jose, California.
HanaVax is a biopharmaceutical company focused on the development of mucosal vaccines. The company is involved in the creation and distribution of nasal vaccines aimed at preventive medicine. HanaVax's innovations are designed to address needs in vaccination. It is based in Tokyo, Japan.
ImmuNovX Biotech focuses on the development of a class of DNA vaccines within the biotechnology sector. The company specializes in a platform technology known as LR3N-CS, which enables the treatment of DNA pathogens to create live-attenuated, replication-defective DNA vaccines through a cell-free manufacturing process. This technology aims to reduce the time and cost associated with the development and deployment of DNA vaccines. It is based in Conshohocken, Pennsylvania.
INOVIO Pharmaceuticals is a clinical-stage biotechnology company that focuses on developing DNA medicines for the treatment of HPV-related diseases, cancer, and infectious diseases. The company has a platform for designing and delivering DNA plasmids, which are small circular DNA molecules that instruct the body's cells to produce proteins that can target and combat diseases. INOVIO's technology employs CELLECTRA® devices to deliver these plasmids without the need for chemical adjuvants, lipid nanoparticles, or viral vectors. Inovio Pharmaceuticals was formerly known as Genetronics Biomedical. It was founded in 1983 and is based in Plymouth Meeting, Pennsylvania.
Genexine is a clinical-stage biotechnology company involved in the development of immunotherapeutics and biopharmaceuticals. The company's offerings include therapeutic DNA vaccines, hyFc long-acting technology, and bioPROTAC platform technology, with a pipeline of products in clinical trials targeting conditions such as cancer, anemia, and growth hormone deficiency. It was founded in 1999 and is based in Seongnam, South Korea.
Loading...